OnCo
peoplePerson

Ho Yeong Lim

A liver cancer oncologist who has been on the steering group of several global HCC trials with strong Asian enrolment.

Ho Yeong Lim has contributed to the systemic-therapy evidence base in hepatocellular carcinoma, including immunotherapy combination trials and Asian subgroup analyses of first-line regimens.

Role
Professor of Medical Oncology; hepatocellular carcinoma
Specialisms
Hepatocellular carcinomaSystemic therapyClinical trials

Papers

1top
TitleJournalYear
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma (IMbrave150)NEJM2020

Key papers

1top
rctNew England Journal of Medicine 2020changed practice
IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer

Patients with advanced liver cancer and good liver function should be offered atezolizumab plus bevacizumab (or durvalumab plus tremelimumab) rather than sorafenib as first treatment; median survival is now around 19 months and about a quarter of patients respond. Endoscopy to treat varices before starting bevacizumab is essential because of bleeding risk. Patients with poorer liver function (Child-Pugh B) or autoimmune disease or transplants were not studied.

Connected

5top

Pages like this

not linked directly; found by shared links

cancers

1
Hepatocellular carcinoma

drugs

1
ApprovedMonoclonal antibody (anti-PD-L1)
Atezolizumab · Tecentriq / Tecentriq Hybreza (SC)

institutions

1
Samsung Medical Center

trials

1
IMbrave150

key papers

1
IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer